文献速递瓣膜病与结构性心脏病

医院外科主动脉瓣置换量与经导管主动脉瓣置换结局的关联

Association Between Hospital Surgical Aortic Valve Replacement Volume and Transcatheter Aortic Valve Replacement Outcomes.
PubMed 文献 · JAMA Cardiol · 2018-01-01

结果显示,单纯高SAVR量与TAVR结局无显著关联,而高TAVR量伴高SAVR量的医院30天死亡最低。

要点

  • 高SAVR量医院更早开展TAVR且TAVR量增长更快。
  • 单纯高SAVR量与TAVR术后结局改善无显著关联。
  • 高TAVR量尤其合并高SAVR量时TAVR术后30天死亡更低。

核心结论

  • 高SAVR量医院更可能快速采纳TAVR,但单纯SAVR量高与TAVR结局改善无关。
  • 积累高TAVR量伴高SAVR量时TAVR术后死亡更低,双高容量医院结局最佳。

研究设计与样本

  • 采用分层逻辑回归调整患者和医院特征,并用多变量比例风险模型分析1年和2年死亡。

主要发现

  • 高SAVR量医院(年均量≥97例/年)更早采纳TAVR,且第1至4年中位TAVR量分别为32 vs 19、48 vs 28、82 vs 38、118 vs 54(P < .001)。
  • 高TAVR量+低SAVR量 vs 低TAVR量+低SAVR量:30天死亡OR 0.85(95%CI 0.72-0.99)。
  • 高TAVR量+高SAVR量 vs 低TAVR量+高SAVR量:30天死亡OR 0.81(95%CI 0.69-0.95)。
  • 高SAVR量+高TAVR量 vs 低SAVR量+低TAVR量:30天死亡OR 0.77(95%CI 0.66-0.89)。

临床怎么用

  • 评估TAVR项目时不应仅依赖SAVR量,应同时关注TAVR累积量及SAVR与TAVR双高容量。
  • 高SAVR量医院更可能早期开展TAVR,可作为项目启动的参考因素之一。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The Centers for Medicare & Medicaid Services national coverage determination for transcatheter aortic valve replacement (TAVR) includes volume requirements for surgical aortic valve replacement (SAVR) for hospitals seeking to initiate or continue TAVR programs. Evidence regarding the association between SAVR volume and TAVR outcomes is limited. OBJECTIVE: To examine the association of hospital SAVR and combined SAVR and TAVR volumes with patient outcomes of TAVR procedures performed within 1 year, 2 years, and for the entire period after initiation of TAVR programs. DESIGN, SETTING, AND PARTICIPANTS: This observational cohort study included 60 538 TAVR procedures performed in 438 hospitals between October 1, 2011, and December 31, 2015, among Medicare beneficiaries. MAIN OUTCOMES AND MEASURES: The associations between SAVR volume, SAVR and TAVR volumes, and risks of death, death or stroke, and readmissions within 30 days were determined using a hierarchical logistic regression model adjusting for patient and hospital characteristics. The association between SAVR and SAVR and TAVR volumes and 1-year and 2-year mortality after TAVR procedures was determined using a multivariable proportional hazard model with a robust variance estimator. The associations for procedures performed within 1 year, 2 years, and for the entire period after initiation of TAVR programs were examined. RESULTS: Among the 60 538 patients, 29 173 were women and 31 365 were men, with a mean (SD) age of 82.3 (8.0) years. Hospitals with high SAVR volume (mean annual volume, ≥97 per year) were more likely to adopt TAVR early and had a higher growth in TAVR volumes over time (median TAVR volume by hospitals with high SAVR volume and low SAVR volume: year 1, 32 vs 19; year 2, 48 vs 28; year 3, 82 vs 38; year 4, 118 vs 54; P < .001). In adjusted analysis, high hospital SAVR volume alone was not associated with better patient outcomes after TAVR. When hospital TAVR and SAVR volumes were jointly analyzed, patients treated in hospitals with high TAVR volume had lower 30-day mortality after TAVR (high TAVR and low SAVR vs low TAVR and low SAVR: odds ratio, 0.85; 95% CI, 0.72-0.99; high TAVR and high SAVR vs low TAVR and high SAVR: odds ratio, 0.81; 95% CI, 0.69-0.95), the effect of which was more pronounced when hospitals also had high SAVR volume. Patients treated in hospitals with high SAVR volume and high TAVR volume had the lowest 30-day mortality (vs hospitals with low SAVR volume and TAVR volume: odds ratio, 0.77; 95% CI, 0.66-0.89). CONCLUSIONS AND RELEVANCE: Hospitals with high SAVR volume are most likely to be fast adopters of TAVR. Hospital SAVR volume alone is not associated with better TAVR outcomes. Accumulating high volumes of TAVR is associated with lower mortality after TAVR, particularly when hospitals have high SAVR volumes. Hospitals with high caseloads of both SAVR and TAVR are likely to achieve the best outcomes.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Mao J, Redberg RF, Carroll JD, et al. Association Between Hospital Surgical Aortic Valve Replacement Volume and Transcatheter Aortic Valve Replacement Outcomes. JAMA Cardiol. 2018. PMID: 30383143. doi:10.1001/jamacardio.2018.3562

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。